NetworkNewsBreaks – Tonix Pharmaceuticals Holdin
Post# of 154
(Total Views: 74)
Posted On: 09/19/2024 7:19:59 PM
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has been awarded a patent by the United States Patent and Trademark Office; the patent is titled “Formulations Comprising Triptan Compounds.” According to the announcement, the patent was issued on Sept. 17, 2024, and is slated to expire in 2030. The company noted that the patent claims a pharmaceutical composition, a method of treating migraine via intranasal administration and an intranasal delivery system for Tosymra(R).
“We believe this patent further solidifies Tosymrain the market as a differentiated drug with a differentiated administration method,” said Tonix Pharmaceuticals CEO Seth Lederman, MD, in the press release. “This new patent targets specific delivery and composition. We are thrilled to have these additional issued patent claims, which add to the intellectual property protection existing for Tosymra.”
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has been awarded a patent by the United States Patent and Trademark Office; the patent is titled “Formulations Comprising Triptan Compounds.” According to the announcement, the patent was issued on Sept. 17, 2024, and is slated to expire in 2030. The company noted that the patent claims a pharmaceutical composition, a method of treating migraine via intranasal administration and an intranasal delivery system for Tosymra(R).
“We believe this patent further solidifies Tosymrain the market as a differentiated drug with a differentiated administration method,” said Tonix Pharmaceuticals CEO Seth Lederman, MD, in the press release. “This new patent targets specific delivery and composition. We are thrilled to have these additional issued patent claims, which add to the intellectual property protection existing for Tosymra.”
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Healthlynked Corp (HLYK) Stock Research Links
Scroll down for more posts ▼